...
Why us? Why us? please click dropdown
4.8/5 out of 3,500+ reviews
Regulated: CQC Registered | 1-5796078466
  • Verified Content: Approved by the Women’s Health Clinic Clinical Team.
  • Educational Use: This is not a substitute for professional medical advice, diagnosis, or treatment.
  • Clinical Assessment: Individual suitability is determined by a clinician; results may vary.
  • Non-NHS: Private healthcare provider only. Pricing varies by treatment and site. Availability varies by clinical location.
  • MEDICAL EMERGENCY:

    If you need urgent help, use NHS 111. For a life-threatening emergency, call 999.

Author Find more about the author
Dr Farzana Khan

Dr Farzana Khan

Verified

Dr Farzana Khan qualified as an MD from the University of Copenhagen in 2003. She has worked in dermatology and obstetrics & gynaecology across the North of England and completed her MRCGP (CCT, 2013) and the Diploma of the Faculty of Sexual & Reproductive Health (2013). Her clinical focus is vaginal health—including dryness/GSM, sexual function concerns, lichen sclerosus, and comfort or volume changes. She offers careful assessment, discusses medical and conservative options first, and considers selected regenerative or aesthetic treatments where appropriate. Dr Farzana also trains clinicians as a KOL/Trainer with Neauvia, Asclepion Laser, and RegenLab (since 2023). Ongoing CPD includes IMCAS, CCR, ACE and expert training in women’s intimate fillers, PRP, and polynucleotide injectables. Her approach is simple: clear explanations, realistic expectations, and shared decision-making.

MD MRCGP DFFP
Was this answer helpful?
Authored and medically reviewed by Dr Farzana Khan on 29 July 2026
Rate Dr Farzana's explanation



Assessment first


Evidence-aware


Safety focused

Women’s Health Clinic FAQ

Can high-dose systemic corticosteroids cause connective tissue weakening that exacerbates stress leaking?

Stress urinary incontinence is influenced by urethral closure, pelvic-floor support, tissue quality and bladder symptoms, so treatment choices should start with the mechanism rather than one isolated factor.

Direct answer

High-dose systemic corticosteroids can affect collagen turnover and tissue resilience in some clinical contexts, so worsening stress leakage may need assessment alongside steroid dose, duration, the reason for treatment, coughing, menopause, weight and pelvic-floor function. Patients should not stop or change steroid treatment because of leakage. The prescribing clinician and pelvic-health team can decide whether tissue factors, pressure load or another bladder problem is contributing.

A useful consultation separates stress leakage from urgency, infection, retention, prolapse, pain and previous-surgery factors before recommending treatment or self-management.


Educational only. This page is educational and does not replace individual assessment. Results vary. Not a cure.

Women's Health Clinic SUI consultation for Can high-dose systemic corticosteroids cause connective tissue weakening that exacerbates stress leaking?

SUI guidance

At a glance

These points help place the question in a safer clinical context.

At a glance

Clinical summary

Tissue

Connective-tissue behaviour can change pelvic support.

Variation

Response to treatment may be less predictable.

Medication

Steroids should never be changed without the prescriber.

Care

Specialist pelvic-health input may be useful.

Important safety note

Seek medical advice promptly for inability to pass urine, fever, blood in urine, recurrent urinary infection symptoms, severe pelvic pain, new neurological symptoms, postmenopausal bleeding or pregnancy concerns.

SUI
Pelvic floor
Tissue
Suitability
Review




Detailed answer

Detailed answer

Connective tissue helps support the urethra, bladder neck and pelvic organs during pressure changes.

Clinical context

Hypermobility, Ehlers-Danlos syndrome or systemic steroid exposure may change tissue resilience, pain, healing or prolapse risk.

Mechanism
Symptoms
Evidence
Alternatives

What is happening

Connective tissue helps support the urethra, bladder neck and pelvic organs during pressure changes.

Why it varies

Hypermobility, Ehlers-Danlos syndrome or systemic steroid exposure may change tissue resilience, pain, healing or prolapse risk.

What assessment checks

These factors do not prove the cause of leakage on their own.

What keeps it safe

Treatment decisions should be individualised and cautious, especially before surgery.

What this means in practice

The page should explain the mechanism without reducing SUI to one cause or promising a single predictable result.

If symptoms are new, severe, mixed, painful, post-operative or pregnancy-related, the plan should pause for medical review.





Patient safety

Why this matters

The same outward leak can have different drivers, and the right next step depends on separating them.

It clarifies the mechanism

Pressure load, tissue quality, sphincter closure, pelvic-floor timing and bladder sensitivity are different issues.

It protects confidence

SUI can affect sport, sex, work, clothing, travel and public life, so it deserves a serious plan.

It prevents over-treatment

Conservative care, medication, surgery or referral suit different people and should not be rushed.

It keeps safety visible

Pain, infection, retention, bleeding, pregnancy concerns or previous pelvic surgery can change the pathway.

An individual plan

The safest approach considers symptom burden, cause, medical history, tissue context, goals and red flags.

This is especially important when medicines, pregnancy, elite sport, connective-tissue disorders or surgery are involved.





Considerations

What to consider

Before deciding what to do, consider the leakage trigger, bladder pattern, pelvic-floor function, bowel symptoms, cough, hormones, medication, pregnancy or surgery history and how symptoms affect daily life.

Consultation priorities

Assessment reviews diagnosis, tissue symptoms, pain, prolapse, previous surgery, medication and bladder pattern.

History
Triggers
Options
Follow-up

First assessment

Assessment reviews diagnosis, tissue symptoms, pain, prolapse, previous surgery, medication and bladder pattern.

Plan discussion

Conservative care may include specialist pelvic-floor physiotherapy, pacing, support garments or pressure management.

Monitoring response

Surgical or procedural options require careful discussion of uncertainty, healing and recurrence risk.

When to reassess

Medication questions should be handled by the prescribing clinician.

Practical expectations

Improvement varies; review should look at leak triggers, quality of life, comfort, bladder emptying and any new symptoms.

Costs, access, prescription decisions, recovery instructions and treatment details should be confirmed directly with the clinic or prescribing clinician before booking.





Common concerns and myths

Common misconceptions

These myths are common because SUI is often discussed too simply.

Myth: connective tissue explains everything

Reality: bladder, pelvic-floor and pressure factors still need assessment.

Myth: hypermobility rules out treatment

Reality: it changes planning rather than automatically removing options.

Myth: steroid concerns mean stopping medicine

Reality: prescription changes must be clinician-led.

Evidence and context

A claim is only useful when it is matched to the woman's actual leakage mechanism and safety profile.

Alternatives

Options may include pelvic-floor physiotherapy, lifestyle support, containment, medicine review, local tissue treatment, surgery or specialist referral depending on the diagnosis.





Safety checklist

Safety checklist

Use these checks before relying on a single explanation or treatment plan for SUI.

Is the leakage pattern clear?

Stress leakage should be separated from urgency, infection, retention, prolapse, pain and mixed symptoms.

Have pressure factors been reviewed?

Cough, constipation, heavy lifting, training load, weight changes and smoking-related cough may all affect symptoms.

Are red flags absent?

Seek medical advice promptly for inability to pass urine, fever, blood in urine, recurrent urinary infection symptoms, severe pelvic pain, new neurological symptoms, postmenopausal bleeding or pregnancy concerns.

Is follow-up planned?

Know who reviews non-response, side effects, worsening leakage, pain, infection symptoms or difficulty passing urine.

Reassuring signs

Proceeding is more reasonable when the diagnosis is clear, expectations are realistic and follow-up is arranged.

Clear diagnosis
No red flags
Review plan

Reasons to pause

Seek medical advice promptly for inability to pass urine, fever, blood in urine, recurrent urinary infection symptoms, severe pelvic pain, new neurological symptoms, postmenopausal bleeding or pregnancy concerns.

Retention
Infection
Severe pain




When to escalate

When to seek medical help

Some urinary or pelvic symptoms should be assessed promptly.

Use NHS 111 online

Unable to pass urine

Inability to pass urine, painful bladder fullness or repeated unsuccessful attempts to void need prompt clinical advice.

Infection symptoms

Fever, burning with feeling unwell, blood in urine, worsening pelvic pain or recurrent UTI symptoms should be assessed.

Pain, bleeding or pregnancy concern

Severe pelvic pain, postmenopausal bleeding, unusual discharge, pregnancy concerns or post-operative deterioration should not be ignored.

Emergency symptoms

Call 999 in a life-threatening emergency, including collapse, chest pain, breathing difficulty or sudden neurological symptoms.

Use NHS 111 for urgent advice or call 999 in a life-threatening emergency. This page is educational and does not replace individual medical assessment.

More clinical detail

Why tissue context matters

Urethral support depends on muscle, connective tissue, mucosa, nerves and pressure control. Hormonal or connective-tissue factors can influence this system without being the only cause.

How to make the consultation more useful

Bring a symptom pattern, medication list, cycle or menopause notes, exercise triggers and any history of prolapse, surgery, pain or recurrent infection.

Next step

Book a continence consultation

A consultation can clarify the SUI mechanism, review conservative and specialist options, and decide what is safe and realistic for your situation.

View Research Sources (12 Sources)
• A multidisciplinary approach to the evaluation and management of interstitial cystitis/bladder pain syndrome: an ideal model of care - PMC
• A randomised-controlled trial pilot study examining the effect of pelvic floor muscle training on steroid hormone concentrations in elderly women with stress urinary incontinence - PMC
• Advances in the molecular pathogenesis and cell therapy of stress urinary incontinence
• Aging-associated modifications of collagen affect its degradation by matrix metalloproteinases - PubMed
• Artificial urinary sphincter erosion: the role of corticosteroids in an unusual presentation
• Cerebrospinal Fluid Leak - PubMed
• Cerebrospinal fluid infection after lumbar nerve root steroid injection: a case report - PMC
• Collagen synthesis and degradation in acutely damaged mouse lung tissue following treatment with prednisolone - PubMed
• Collagen synthesis is not altered in women with stress urinary incontinence - PubMed
• Comparison of Biomechanical Properties of Dura Mater Substitutes and Cranial Human Dura Mater : An In Vitro Study - PMC
• Congenital Disorders of the Human Urinary Tract: Recent Insights From Genetic and Molecular Studies - PMC
• Corticosteroid Corticosteroid-Induced Myopathy Induced Myopathy - MyastheniaGravis.cz

These 12 source names are selected from 309 curated sources. Additional reviewed material included peer-reviewed clinical papers, evidence reviews; duplicate and low-relevance records were removed before display.

Educational only. This information is for education only and is not a substitute for professional medical advice, diagnosis or treatment. Results vary. Not a cure.

  • Clinical Assessment: Individual suitability is determined by a clinician; results may vary.
  • Non-NHS: Private healthcare provider only. Pricing varies by treatment and site. Availability varies by clinical location.